MDT

99.69

-0.44%↓

145.75

-0.67%↓

VEEV

239.89

+1.29%↑

HQY

97.32

+1.57%↑

PHR.US

17.54

+2.57%↑

MDT

99.69

-0.44%↓

145.75

-0.67%↓

VEEV

239.89

+1.29%↑

HQY

97.32

+1.57%↑

PHR.US

17.54

+2.57%↑

MDT

99.69

-0.44%↓

145.75

-0.67%↓

VEEV

239.89

+1.29%↑

HQY

97.32

+1.57%↑

PHR.US

17.54

+2.57%↑

MDT

99.69

-0.44%↓

145.75

-0.67%↓

VEEV

239.89

+1.29%↑

HQY

97.32

+1.57%↑

PHR.US

17.54

+2.57%↑

MDT

99.69

-0.44%↓

145.75

-0.67%↓

VEEV

239.89

+1.29%↑

HQY

97.32

+1.57%↑

PHR.US

17.54

+2.57%↑

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Avatud

SektorTervishoid

41.7 2.16

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

40.29

Max

41.87

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+31.49% upside

Turustatistika
By TradingEconomics
Turukapital	-639K 3.2B
Eelmine avamishind	39.54
Eelmine sulgemishind	41.7

Uudiste sentiment

By Acuity

50%

164 / 373 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. jaan 2026, 21:14 UTC

Suurimad hinnamuutused turgudel

Ventyx Biosciences Gains on Report of Possible $1 Billion Eli Lilly Deal

6. jaan 2026, 19:23 UTC

Omandamised, ülevõtmised, äriostud

OneStream to Go Private Through $6.4 Billion Hg Acquisition

6. jaan 2026, 17:41 UTC

Suurimad hinnamuutused turgudel

Blink Charging Shares Rise as EV Chargers Begin Accepting Cryptocurrency

6. jaan 2026, 15:46 UTC

Omandamised, ülevõtmised, äriostud

Advent International Leads InPost Takeover Offer, Sky News Says

6. jaan 2026, 15:37 UTC

Suurimad hinnamuutused turgudel

Terrestrial Energy Shares Rise After DOE Agreement For Nuclear Plant Development

6. jaan 2026, 23:46 UTC

Market Talk

Nikkei May Decline After Hitting Record High -- Market Talk

6. jaan 2026, 23:35 UTC

Market Talk

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

6. jaan 2026, 23:19 UTC

Market Talk

Greatland 2Q Gold Output Strong, Sales Soft -- Market Talk

6. jaan 2026, 22:53 UTC

Market Talk

WiseTech, REA and CAR Look Best Insulated From AI Threat -- Market Talk

6. jaan 2026, 22:03 UTC

Omandamised, ülevõtmised, äriostud

Staar Surgical: Merger Proposal Received 14.9M Votes For and 27.3M Against

6. jaan 2026, 22:03 UTC

Omandamised, ülevõtmised, äriostud

Staar Surgical, Which Earlier Reported Stockholder Rejection of Sale to Alcon, Reports Vote Totals

6. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. jaan 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. jaan 2026, 21:12 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6. jaan 2026, 21:12 UTC

Market Talk

Commodity Demand Helps Canada Reduce Reliance on Trade With U.S. -- Market Talk

6. jaan 2026, 20:59 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Ventyx Biosciences Gains on Report of Possible $1B Eli Lilly Deal

6. jaan 2026, 20:40 UTC

Omandamised, ülevõtmised, äriostud

Acquisition of Ventyx Would Bring Lilly Into Emerging Category of Pills for Inflammation-Related Conditions -- WSJ

6. jaan 2026, 20:40 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly Nears Deal for Biotech Ventyx -- WSJ

6. jaan 2026, 20:40 UTC

Omandamised, ülevõtmised, äriostud

Deal Could Be Announced Imminently, Sources Say -- WSJ

6. jaan 2026, 20:40 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly in Advanced Talks to Buy Ventyx Biosciences For Over $1B, Sources Say -- WSJ

6. jaan 2026, 20:01 UTC

Market Talk

Oil Futures Give Back Post-Venezuela Incursion Gains -- Market Talk

6. jaan 2026, 19:52 UTC

Market Talk

U.S. Natural Gas Falls Awaiting Colder Weather -- Market Talk

6. jaan 2026, 19:46 UTC

Omandamised, ülevõtmised, äriostud

Under Armour Stock Rises After the 'Warren Buffet of Canada' Boosts Its Stake -- Barrons.com

6. jaan 2026, 19:08 UTC

Omandamised, ülevõtmised, äriostud

OneStream to Go Private Through $6.4B Hg Acquisition

6. jaan 2026, 18:28 UTC

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Sandisk, Nvidia, AMD, Palantir, OneStream, SoFi, Microchip, and More -- Barrons.com

6. jaan 2026, 17:20 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

6. jaan 2026, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

6. jaan 2026, 15:57 UTC

Market Talk

Crude Futures Ease Back From Early Gains -- Market Talk

6. jaan 2026, 15:34 UTC

Market Talk

Tulu

Bank of Montreal Expects to Exit 2027 With ROE Hitting 15% Target -- Market Talk

6. jaan 2026, 15:27 UTC

Market Talk

German Inflation Won't Fall Much Further in 2026 -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

31.49% tõus

12 kuu keskmine prognoos

Keskmine 53.91 USD 31.49%

Kõrge 60 USD

Madal 44 USD

Põhineb 13 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

Osta

Hoia

Müü

Põhineb 13 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

164 / 373 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.